Nanox Signs Distribution Agreement with Associated X-Ray Imaging to Expand Nanox.ARC Adoption Across New England

Expands Nanox’s growing U.S. distribution network with a leading New England-based medical imaging provider

PETACH TIKVA, Israel — September 4 2026 — Nano-X Imaging Ltd. (“Nanox”, or the “Company”, NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has entered into a distribution agreement with Associated X-Ray Imaging Corp., a New England-based provider of medical imaging equipment and services, specializing in X-ray, MRI, and CT systems, to support deployment of the Nanox.ARC across the region.

Under the agreement, Associated X-Ray Imaging will market, distribute, and support the Nanox.ARC, an FDA-cleared, multisource 3D digital tomosynthesis system, leveraging its established regional presence and service infrastructure across New England. The collaboration is expected to support Nanox’s ongoing U.S. commercial execution by expanding access to advanced 3D imaging within additional outpatient and community-based clinical settings.

Associated X-Ray Imaging has been serving healthcare providers across New England for decades, supplying and servicing a broad range of diagnostic imaging technologies for hospitals, imaging centers, and specialty clinics.

“We continue to build our U.S. commercial footprint through focused regional distribution partnerships that are aligned with our deployment strategy,” said Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox. “Associated X-Ray Imaging brings long-standing customer relationships, strong technical expertise, and a deep understanding of the New England imaging market. This partnership supports our efforts to expand measured adoption of the Nanox.ARC across additional clinical environments.”

“We are pleased to partner with Nanox and add the Nanox.ARC to our imaging portfolio,” said John Olenio, Owner, Founder and Chief Executive Officer of Associated X-Ray Imaging Corp. “We believe the Nanox.ARC offers a compelling approach to 3D imaging that aligns with our focus on providing practical diagnostic solutions supported by reliable service across New England.”

This agreement represents another step in Nanox’s U.S. channel partner strategy, as the Company continues to expand a diversified distribution network to support commercial deployment of the Nanox.ARC across targeted U.S. regions.

About Associated X-Ray Imaging Corp

Founded in 1975, Associated X-Ray Imaging Corp. is a New England-based provider of medical imaging equipment, service, and supplies. The company supports hospitals, imaging centers, and specialty clinics with diagnostic imaging technologies across multiple modalities, including X-ray, MRI, and CT, supported by a regional sales and service organization. For more information, visit www.associatedxray.com

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.

Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.

Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.

The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.

By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision.

Forward-Looking Statements

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com

Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com